UK

Life Sciences IPOs – 5 things to consider

Michael Bloch

After spending all day last Wednesday at Biotech & Money’s IPO workshop presenting and talking to Life Sciences start ups about their IPO plans, we thought it might be interesting to bring together some of our key thoughts on IPO preparedness. Companies thinking about an IPO can never start planning too early.  IPO planning and Read More

UK Court of Appeal asks the CJEU when Markush claims will be sufficiently specific for Article 3(a) of the SPC Regulation

Steven Baldwin

The Appellants in this action, Sandoz and Hexal, are appealing Arnold J’s decision to uphold SPC/GB07/038 on the basis that the Markush formulae in the basic patent are sufficient to satisfy the requirements of Article 3(a) of the SPC Regulation (Regulation (EC) No 469/2009). We have previously commented on the facts here and the first Read More

Beyond the pill – are digital health deals set to spike?

Matthew Appleton

Transactions between big pharmaceutical companies and start-ups working on potentially highly disruptive but beneficial technologies in the healthcare space have not taken off as fast as some expected. That could be about to change. It probably wasn’t meant to take centre stage, but the small white circle on the arm of UK Prime Minister Theresa Read More

“Granted means Granted” – CJEU rules that End of Procedure Notice not enough to satisfy Art 3(b) SPC Regulation

Steven Baldwin

At the end of last week, whilst heads were turned by the UK Prime Minister’s pre-dawn flight to Brussels and EU Brexit negotiators tweeting pictures of white smoke billowing from Vatican chimneys, the CJEU handed down its decision in the Merck Sharp & Dohme Corporation v Comptroller General of Patents, Designs and Trade Marks case. Read More

Brexit: EMA’s regulatory guidance on centrally approved medicinal products – the present state of play

Jacqueline Bore

The champagne bottles have been drained in Amsterdam and tears dried in Milan and Bratislava but the serious work of mapping out the practical implications of Brexit continues at the European Medicines Agency (EMA). The EMA and the European Commission issued a Notice in May 2017 confirming that “unless the withdrawal agreement establishes another date” Read More